Review of a case of Down syndrome T-ALL with complex karyotype and treatment response

Photo by National Institute of Allergy and Infectious Diseases / Unsplash

Frontiers in Medicine Published May 18, 2026 Medically reviewed May 18, 2026 DOI ↗ By Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

Key Takeaway

Consider the poor characterization and lack of guidelines for treating Down syndrome T-ALL when making clinical decisions.

This publication is a narrative review and case report describing a single 7-year-old boy with Down syndrome and T-cell acute lymphoblastic leukemia. The review's scope is to characterize this rare clinical entity and discuss treatment.

The authors report that the patient's leukemia had a complex karyotype with translocation t(1;14)(p32;q11) and deletion of chromosome 9p. RNA sequencing was negative for a fusion transcript, and pathogenic variants were found in NOTCH1 and FBXW7. The patient received chemotherapy according to the AIEOP-BFM ALL 2017 study protocol and achieved a favorable response with minimal residual disease negativity after 15 months of follow-up.

The authors note multiple severe complications and significant treatment modifications due to toxicity. They acknowledge key limitations, stating that this entity remains poorly characterized both genetically and clinically, and there are no standardized guidelines for treating these rare and fragile patients.

The practice relevance is that improved knowledge and characterization of Down syndrome T-ALL might inform clinicians about treatment decision making for this very rare disease. The authors suggest the findings indicate a sporadic leukemogenesis origin, distinct from the pathway associated with B-cell precursor ALL.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

BackgroundChildren with Down syndrome (DS) show a higher incidence of acute lymphoblastic leukemia (ALL) compared to general population. They are almost entirely affected by B-cell precursor ALL, linked to the constitutional chromosome 21 trisomy and associated with recurrent mutational patterns. The occurrence of T-cell ALL (T-ALL) is extremely rare in DS patients, with only few reports described. This entity remains poorly characterized either genetically and clinically, and there are no standardized guidelines for the treatment of these rare and fragile patients. Here we describe the case of a child with DS and T-ALL and provide comprehensive genetic characterization of his disease.Case reportA previously well 7-year-old boy with DS was diagnosed with T-ALL presenting with leukocytosis, mediastinal mass and central nervous system involvement (CNS2). Genetic studies showed a complex karyotype with the translocation t(1;14)(p32;q11) and deletion of chromosome 9p. RNA sequencing was negative for fusion transcript. Next-generation sequencing analysis for somatic mutations on DNA material showed pathogenic variants in NOTCH1 and FBXW7. Chemotherapy was started according to AIEOP-BFM ALL 2017 study. During induction phase, the patient suffered from multiple severe complications, requiring significant treatment modifications and an anthracycline-free induction. However, the patient presented favorable response achieving minimal residual disease negativity. He is currently on maintenance therapy 15 months from the diagnosis.ConclusionThis case provides the first detailed genetic characterization of T-ALL in a child with DS. The findings of typical T-ALL somatic mutations and genetic alterations suggest a sporadic leukemogenesis origin, distinct from the specific pathway associated with B-cell precursor ALL. We confirm the rarity of this entity and the extreme susceptibility to treatment complications. An improved knowledge and characterization of DS T-ALL might be helpful to inform clinicians about treatment decision making for this very rare disease.